FDA Probes Yaz, Others Over Blood Clot Risks

Law360, New York (May 31, 2011, 10:12 PM EDT) -- The U.S. Food and Drug Administration said Tuesday that it launched an investigation into whether birth control pills that contain drospirenone, like Bayer AG's Yasmin and Yaz, put users at increased risk of blood clots.

Two recently released studies cited by the FDA showed that the drugs increase the risk of venous thromboembolism by up to two to three times compared with other birth control pills. Other studies, though, have not found drospirenone to be riskier than its competition.

“The FDA is currently evaluating the conflicting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.